Ruixin Medical Secures Nearly RMB 100 Million in Series D Funding to Advance AI-Driven Precision Cardiac Care

May 27, 2026 15:19 CST Updated 15:19

RaysightMed

Medical Imaging Product Developer

Good News | RaysightMed Successfully Closes Nearly RMB 100 Million Series D Financing.Through the coordinated efforts of Guangzhou’s municipal and district-level state-owned capital investment platforms, this round of financing was successfully closed in Yuexiu District, Guangzhou, with Guangzhou Biomedical and Health Industry Investment Co., Ltd. (hereinafter referred to as "Guangzhou Health Investment") as the lead investor and Guangzhou Yuefu Fund Management Co., Ltd. (hereinafter referred to as "Yuefu Fund") as a co-investor.

The successful closing of this financing round underscores the industrial investment fund's strong recognition of RaysightMed's core technologies, industrial value, and commercialization progress. It will inject robust momentum into the company's overall pipeline development, rapid business growth, and overseas market expansion. Furthermore, through this financing round, RaysightMed will deepen its forward-looking strategic deployment in AI-driven vascular interventional surgical robotics, develop an integrated AI-and-robotics diagnostic and therapeutic platform, seize leadership in the future market for minimally invasive and precision interventions, and establish solid dual competitive barriers in both technology and commercialization.

Since its establishment, RaysightMed has consistently adhered to its brand positioning—the "Leader in Intelligent Integrated Solutions for Precision Cardiac Diagnosis and Treatment." Guided by its mission and brand slogan, "Safeguarding the Enduring Rhythm of Life with Intelligent Technology," the company focuses on the precision cardiovascular diagnosis and treatment sector. With hard technology innovation as its core driving force, RaysightMed integrates cutting-edge technologies such as artificial intelligence, hemodynamic simulation, and surgical robots to build an integrated intelligent diagnosis and treatment platform for cardiovascular and cerebrovascular diseases, covering preoperative diagnosis, intraoperative diagnosis and treatment, and postoperative health management. By developing a comprehensive product matrix spanning multiple clinical scenarios, the company is fully dedicated to resolving critical pain points in clinical diagnosis and treatment. Meanwhile, RaysightMed has ranked in the Top 20 of the Arterial Network's "Future Healthcare 100" series rankings for consecutive years, signifying the industry's high recognition of the company's technological innovation, commercialization achievements, and comprehensive strength in the field of AI-driven precision cardiovascular diagnosis and treatment.

Among them, the core flagship product AngioQFA, leveraging its cutting-edge technological architecture and precise clinical value, enables a one-stop assessment of fractional flow reserve (FFR) and the index of microcirculatory resistance (IMR). It profoundly empowers precise intra-procedural evaluation and optimizes clinical decision-making, establishing itself as a benchmark solution for precision coronary diagnosis and treatment. Following its market launch, it has received widespread recognition from industry experts in China, pioneering a new direction in intravascular functional diagnosis and treatment. Currently, RaysightMed has established a strategic partnership with Blue Sail Medical for the global market, propelling China's original innovations onto the international stage.

Another core product, Raysight CT-FFR (CTFFR), continues to advance its clinical implementation and application expansion. As a benchmark product in the field of non-invasive coronary functional assessment in China, it consistently supports clinical diagnosis and treatment. Currently, RaysightMed and iFlytek Imaging are fully committed to driving the clinical adoption of the product and exploring new application scenarios. In addition, RaysightMed's newly deployed Intracardiac Echocardiography (ICE) focuses on precise intracardiac imaging diagnosis, further optimizing the comprehensive preoperative and intraoperative diagnostic and treatment closed-loop for electrophysiology and structural heart procedures. Meanwhile, RaysightMed's robust AI technological foundation enables clearer ICE imaging that better meets clinical requirements.

Looking ahead, RaysightMed will remain guided by clinical needs, continuously deepen its focus on the precision cardiovascular diagnosis and treatment segment, consolidate its market leadership in AngioQFA, accelerate the commercialization of pipeline products including Raysight FFR, Raysight ICE, and surgical robots, promote the large-scale clinical application of innovative medical devices, and facilitate the quality enhancement and upgrading of cardiovascular diagnosis and treatment in China, ultimately benefiting a broad patient population.

RaysightMed CEO Zheng Lingxiao stated that he is pleased to see the company's efforts recognized. Over the past few years, Chinese medical device enterprises have made significant strides in exploring clinical needs, product innovation, and commercial implementation. Moving forward, RaysightMed will continue to advance, remain deeply rooted in Chinese clinical practice, and strive to grow into a global smart healthcare enterprise.

Feng Zhizhong, Deputy General Manager of Guangzhou Health Industry Investment, stated, "We have strong confidence in RaysightMed's robust technological foundation and extensive clinical product portfolio. We also highly recognize the team's consistent capability in driving the clinical implementation and commercialization of innovative technologies. Furthermore, we are even more optimistic about RaysightMed's strategic deployment in AI-powered surgical robots. The fund will continue to support the sustainable development of RaysightMed."

Yang Qichao, head of Yuefu Fund Company, stated that RaysightMed’s forward-looking strategic deployment and investment in AI surgical robots closely align with the development trajectory of future industries and the strategic planning of Yuexiu District, Guangzhou. Yuefu Fund is highly optimistic about this collaboration.